Type 1 diabetes is associated with increased intestinal inflammation and decreased
abundance of butyrate-producing bacteria. We investigated the effect of butyrate on
inflammation, kidney parameters, HbA1c, serum metabolites and gastrointestinal symptoms
in persons with type 1 diabetes, albuminuria and intestinal inflammation. We conducted a
randomized placebo-controlled, double-blind, parallel clinical study involving 53 participants
randomized to 3.6 g sodium butyrate daily or placebo for 12 weeks. The primary endpoint …

Background: Fecal calprotectin, a marker of inflammation, is increased in persons with type
1 diabetes (T1D) and kidney disease. This may be explained by a reduction of butyrate-
producing bacterial species in the gut. Butyrate supplementation has beneficial effects on
intestinal inflammation in inflammatory bowel disease but has never been tested in persons
with T1D. Objective: To assess the effect of sodium butyrate on fecal calprotectin and other
inflammatory markers, kidney parameters, hba1c and gastrointestinal symptoms in persons …